← Therapeutics
Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry
NST-001 by NeuroSystec for tinnitus
Also known as: NST-001, Neuroject Injection Set, NST-CP-02, NCT00957788
NeuroSystec Corporation
Company
NeuroSystec Corporation
Program Type
Therapeutic
Modality
Small Molecule
Stage
Phase 1
Status
Discontinued
Target Gene
—
Route / Mode
Inner-ear injection
Confidence
83%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-09
Geography
Belgium, France
Population
adult, tinnitus, profound-hearing-loss, inner-ear-delivery
Trial IDs
1
Mechanism
Experimental drug delivered directly to the inner ear using the Neuroject injection set for severe unilateral tinnitus.
Indications
Notes
Verified as a historical NeuroSystec-sponsored Phase 1 tinnitus safety/feasibility study. The study was terminated and no current follow-on development was verified in this pass.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, company, stage, status, route, indications, populationTags...
IDs: NCT00957788, NST-CP-02, NST-001
Key Events
Clinical Trials (1)
Data Checks
historical-completed-studyterminated-studyno-posted-results-confirmed
Related Programs
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
AC102 by AudioCure Pharma
Company: AudioCure Pharma · Small Molecule · Phase 2
SPI-1005 by Sound Pharmaceuticals
Company: Sound Pharmaceuticals · Small Molecule · Phase 3
ACOU085 by Acousia Therapeutics
Company: Acousia Therapeutics GmbH · Small Molecule · Phase 2
CIL001 (Paliroden) by Cilcare
Company: Cilcare SAS · Small Molecule · Phase 1/2